Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction

Shigeru Matsui, Junnichi Ishii, Fumihiko Kitagawa, Atsuhiro Kuno, Kousuke Hattori, Makoto Ishikawa, Masanori Okumura, Shino Kan, Tadashi Nakano, Hiroyuki Naruse, Ikuko Tanaka, Masanori Nomura, Hitoshi Hishida, Yukio Ozaki

Research output: Contribution to journalArticlepeer-review

89 Citations (Scopus)


Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24. h (mean of 7.5. h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P= 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (≥3.1. ng/mL of median value) than those without (20% vs. 5.8%, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24. h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.

Original languageEnglish
Pages (from-to)220-225
Number of pages6
Issue number1
Publication statusPublished - 05-2010

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction'. Together they form a unique fingerprint.

Cite this